Earnings call transcript: Logista’s Q2 2026 results show revenue growth

Logista reported H1/Q2 2026 revenues up 3% to €6.6B, but net profit fell 10% to €136M and adjusted EBIT declined 4% as lower inventory gains and restructuring/impairment costs weighed on results. Management reaffirmed full-year 2026 guidance for mid-single-digit adjusted EBIT growth excluding inventory gains and said it expects to maintain at least last year’s dividend. Shares were weak in premarket, down 0.91%, as investors focused on the earnings decline and macro/geopolitical cost risks.

Analysis

The main read-through is not the headline miss; it’s that the business is increasingly trading like a rate- and policy-sensitive cash compounder rather than a pure tobacco distributor. The inventory revaluation tailwind is fading into a less predictable, more timing-dependent earnings lever, which means incremental upside now depends more on execution in pharma, temperature-controlled logistics, and cost discipline than on the old tobacco pass-through math. That shifts the stock’s quality-of-earnings profile lower and raises the bar for multiple expansion even if guided EBIT growth is met.

The second-order winner set is the diversified logistics ecosystem: pharma, specialty distribution, and contract logistics names with less exposure to excise-tax-driven volume erosion should gain relative appeal as investors look for growth that is not hostage to tobacco policy. The loser set is the legacy tobacco distribution corridor, especially in France, where volume decay plus illicit substitution can compress route density and warehouse leverage faster than management can offset with pricing or overhead actions. If excise pressure persists, the real margin risk is not one quarter of lower volumes, but a structural under-absorption of fixed costs that leaks into both operating margin and cash conversion over the next 2-4 quarters.

The geopolitical oil angle is nuanced: near-term fuel cost pressure is partially hedged through pass-through, but timing mismatches can still hit quarterly optics and force temporary working-capital drag. Higher rates are a latent positive because of cash balances/credit-line economics, so the market may be over-penalizing the macro sensitivity while underappreciating the balance-sheet income cushion. The contrarian view is that the selloff could be too focused on the current inventory normalization and not enough on the embedded option value from pharma M&A and service expansion, which could re-rate the asset mix if executed within 6-12 months.

Bottom line: this is a “show me” quarter, not a broken story. If management can keep mid-single-digit EBIT growth ex-inventory while converting the portfolio toward higher-growth, less regulated services, the stock can re-earn a premium; if not, it becomes a slow-growth, cash-yield name vulnerable to multiple compression as the tobacco engine keeps decelerating.

Key Decisions for Investors

• Long LOGISTA/short a diversified European tobacco-adjacent distributor basket for 3-6 months: own the name only if you believe management can convert M&A and pharma growth into a higher-quality mix; otherwise expect underperformance as inventory noise fades.
• Buy 6-12 month out-of-the-money calls on LOGISTA only on pullbacks after the premarket reaction settles; the cleaner setup is a volatility reset rather than chasing the first downtick, with upside tied to acquisition announcements and a better mix story.
• Pair long a pharma/logistics beneficiary such as DSV or DHL vs. short a tobacco-distribution proxy over the next 2 quarters: the market is likely to reward secular volume growth and punish excise-dependent route-density erosion.
• If using event-driven exposure, wait for confirmation of any pharma or temperature-controlled M&A before adding risk; pre-positioning now carries mediocre risk/reward because the near-term catalyst path is dominated by normalization, not surprises.
• For income-oriented holders, maintain but hedge with short-dated puts into the next two earnings prints; downside is mainly multiple compression if France worsens or oil timing effects bleed into margins, while dividend support limits absolute drawdown.